Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03702140

Enrollment

Registered

2018-10-10

Start date

2018-10-09

Completion date

2025-10-08

Last updated

2021-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Brief summary

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in osteoporosis patients: 1. The administration period of teriparatide is less than 6 months and thereafter, denosumab for 24 months. 2. The administration period of teriparatide is from 6 to 12 months and thereafter, denosumab for 24 months. 3. The administration period of teriparatide is more than 12 months and thereafter, denosumab for 24 months.

Interventions

DRUGTeriparatide, Forteo® or Teribon

To examine the effects of terimaratide less than 6 months in osteoporosis

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

20 Years to 120 Years

Healthy volunteers

Inclusion criteria

* Osteoporotic patients who want to take teriparatide and denosumab

Exclusion criteria

* Patients who are allergic to teriparatide or denosumab Patients who are pregnant or breast-feedin

Design outcomes

Primary

Measure	Time frame
Bone mineral density	Change from Baseline Values at 1 year

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026